Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2210261 | 1.00 | KDM4E (0.35) | KDM4EHTTSMN1; SMN2VNN1DDR2 | |
| SCHEMBL2209797 | 0.92 | MAPK14 (0.36) | KDM4EMAPK14ELANECYP3A4P2RX3 | |
| SCHEMBL2209792 | 0.92 | MAPK14 (0.36) | KDM4EMAPK14ELANECYP3A4P2RX3 | |
| SCHEMBL2206917 | 0.92 | VNN1 (0.34) | VNN1ELANEBRAFP2RX3 | |
| SCHEMBL2211768 | 0.92 | VNN1 (0.34) | VNN1ELANEBRAFP2RX3 | |
| SCHEMBL2211289 | 0.90 | MAPK14 (0.34) | MAPK14CYP3A4P2RX3 | |
| SCHEMBL2210663 | 0.90 | MAPK14 (0.34) | MAPK14CYP3A4P2RX3 | |
| SCHEMBL2211451 | 0.90 | ELANE (0.38) | KDM4EHTTSMN1; SMN2VNN1ELANE | |
| SCHEMBL2211459 | 0.90 | ELANE (0.38) | KDM4EHTTSMN1; SMN2VNN1ELANE | |
| SCHEMBL1322935 | 0.89 | KDM4E (0.36) | KDM4EHTTSMN1; SMN2VNN1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | KDM4E 3564/4885HTT 2507/4885SMN1; SMN2 1479/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | KDM4E 3564/4885HTT 2507/4885SMN1; SMN2 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.